Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856778 · ClinicalTrials.gov registry record · NA
Virtue® Male Incontinence Sling Study
A NA study of Stress Urinary Incontinence, sponsored by Coloplast A/S.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 11
- Study locations
NCT00856778: Completed NA study of Stress Urinary Incontinence, sponsored by Coloplast A/S.
NCT00856778 is a NA study of Stress Urinary Incontinence that has completed, run by Coloplast A/S. The registered enrollment target is 98 participants, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (39% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00856778, a NA study of Stress Urinary Incontinence, has completed, sponsored by Coloplast A/S.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a multi-center, global study that will assess the effectiveness and patient satisfaction of the male incontinence sling 12 months after implant as well as the safety profile of the product.
Primary Outcome
Patient satisfaction using the Patient Global Impression of Improvement (PGI-I. Definition of Success: \>50% responding "very much better" or "much better".
Conditions Studied
Interventions
- DEVICE Virtue® Male Incontinence Sling
Study Locations (11)
California
- Kaiser Permanente - Los Angeles
- Stanford University Medical Center - Stanford
Quebec
- Mortimer S Davis Jewish General Hospital - Montreal
- CHUS Hopital Fleurimont - Sherbrooke
Florida
- Winter Park Urology Associates - Orlando
Indiana
- Northeast Indiana Research - Fort Wayne
Michigan
- Wayne State University - Dearborn
New York
- NYU Urology Associates - New York
North Carolina
- McKay Urology - Charlotte
Texas
- University of Texas-M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-01 |
| Phase | NA |
What the finished NCT00856778 record still lists
NCT00856778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Virtue® Male Incontinence Sling is the first listed.
NCT00856778 lists 11 locations in 9 states (California, Quebec, Florida).
Frequently Asked Questions
What is clinical trial NCT00856778 about?
NCT00856778 is a clinical study titled "Virtue® Male Incontinence Sling Study". This study is a multi-center, global study that will assess the effectiveness and patient satisfaction of the male incontinence sling 12 months after implant as well as the safety profile of the product.
What is the current status of trial NCT00856778?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2009-01. Estimated completion is 2011-01.
What conditions does trial NCT00856778 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence.
What interventions are being tested in trial NCT00856778?
The interventions under investigation include: Virtue® Male Incontinence Sling (DEVICE).
Who is sponsoring clinical trial NCT00856778?
This trial is sponsored by Coloplast A/S, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00856778 being conducted?
This trial has 11 study locations across California, Florida, Indiana, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00856778's enrollment target sits among peer trials
98 17th of 35 higher than 19 of 35 other Stress Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
-
Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery
RECRUITING · NA
-
Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy
RECRUITING · NA
-
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia